10x Genomics — Third Quarter 2026 Earnings Summary

10x Genomics reported third-quarter 2026 revenue of $150.7 million, a 1% increase from the prior year period, driven by strong consumables sales and the commercial launch of its Atera platform. The company achieved a gross margin of 75% and reduced its operating loss to $16.1 million, while net loss narrowed to $19.4 million compared to the previous year. Management raised its full-year 2026 revenue guidance to a range of $625 million to $635 million, reflecting continued growth in its core business excluding non-recurring litigation settlements.